| MA |
DI | WO |
DO |
VR | ZA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VM | NM | VM | NM | VM | NM | VM | NM | VM | NM | VM | NM |
- Maandag: namiddag
- Woensdag: voormiddag
- Vrijdag: namiddag
Dr. Bossuyt is niet geconventioneerd
Raadpleging Imeldaziekenhuis
Contact: 015 50 51 11
Raadpleging Somedi
maandag voormiddag
Contact: 015 25 89 11
Curriculum
Peter Bossuyt is a gastroenterologist at the IBD clinic in the Imelda General Hospital in Bonheiden, Belgium. He is also Co-director of the Imelda GI Clinical Research Centre in Bonheiden. Dr Bossuyt studied medicine at the Catholic University of Leuven, Belgium, and graduated in 2004 with magna cum laude. He pursued his GI fellowship in Kortrijk, Roeselare, Bonheiden and Leuven. After completing his GI fellowship, he took up a fellowship in advanced endoscopy at the Academic Medical Centre, Amsterdam. Between 2010 and 2015 he was a consulting staff member for endoscopic ultrasound at the University Hospitals of Leuven. In 2015 he started a PhD entitled, Value of endoscopic scoring and imaging for the prognosis and follow up of IBD, with Professor Séverine Vermeire as promotor. His research focuses on clinical trials in IBD and the definitions of endoscopic and imaging targets in IBD. He is a pioneer in working with e-health tools in IBD in Belgium. He is an editorial board member of the Journal of Crohn’s and Colitis, past-chair of the Scientific Committee and current secretary of the Belgian IBD Research and Development Group, and board member of ECCO’s Clinical Research Committee, ClinCom. He has (co-)authored >70 papers in international peer-reviewed journals (h-index 18) and was invited speaker at multiple international congresses.
Dr Peter Bossuyt is maagdarmspecialist in de IBD kliniek van het Imeldaziekenhuis in Bonheiden. Hij is co-director van het Imelda GI clinical research center in Bonheiden. Dr Bossuyt studeerde geneeskunde aan de KU Leuven en promoveerde met magna cum laude in 2004. Hij volgde zijn opleiding tot maagdarmspecialist in Kortrijk, Roeselare, Bonheiden en Leuven. Na zijn promotie tot gastroenteroloog volgde hij een bijkomende opleiding in de gespecialiseerde endoscopie aan het Amsterdam Medisch Centrum. Tussen 2010 en 2015 was hij consultent-staflid voor echoendoscopie in Gasthuisberg. In 2015 startte hij een doctoraatsonderzoeksproject ‘Value of endoscopic scoring and imaging for the prognosis and follow up of IBD’ onder supervisie van Prof Vermeire aan de KU Leuven. Hij is een pionier in het werken met e-health bij inflammatoire darmziekten in België. Hij is lid van de editorial board van de Journal of Crohn’s and Colitis, past-chair van het wetenschappelijk comité en huidig secretaris van de Belgisch IBD onderzoeksgroep (BIRD) en lid van het clinical research committee van de Europese IBD vereniging. Hij publiceerde >70 onderzoeksartikels in internationale tijdschriften (h-index 18) en was spreker op talrijke internationale congressen.
twitterfeed IBD kliniek
5 belangrijkste publicaties:
Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Bossuyt P, Nakase H, Vermeire S, de Hertogh G, Eelbode T, Ferrante M, Hasegawa T, Willekens H, Ikemoto Y, Makino T, Bisschops R. Gut. 2020 Jan 8:gutjnl-2019-320056. doi: 10.1136/gutjnl-2019-320056. Online ahead of print.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. Lancet. 2018 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31.
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR; SECURE study group. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R, Laurent V, Zappa M, Savoye-Collet C, Pariente B, Filippi J, Baert F, D'haens G, Laharie D, Peyrin-Biroulet L, Vermeire S; Tailorix study group. Clin Gastroenterol Hepatol. 2020 Apr 28:S1542-3565(20)30597-8. doi: 10.1016/j.cgh.2020.04.052. Online ahead of print.
Head-to-head trials in inflammatory bowel disease: past, present and future. Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):365-376. doi: 10.1038/s41575-020-0293-9. Epub 2020 Apr 17.
Grant support: VIB grand challenges Grant 2.500.000 Euro
Externe links